Revance Therapeutics Inc Quick Ratio (RVNC) starting from the third quarter 2024 to third quarter 2023, Financial Strength Trends, Rankings, Financial Ratios - CSIMarket
CSIMarket Company Name, Ticker, Customers, else..
 


• Quick Ratio
• Working Capital
• LT Debt to Equity
• Debt to Equity
• Leverage Ratio
• Tangible Leverage
• Interest Coverage
• Debt Coverage
• Work. Cap. Per Revenue
Revance Therapeutics Inc   (NASDAQ: RVNC)

Revance Therapeutics Inc 's Quick Ratio

RVNC's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth


Regardless of the sequential decrease in Current Liabilities, during the third quarter 2024, Quick Ratio deteriorated to 2.31 a new company low.

Within Major Pharmaceutical Preparations industry 273 other companies have achieved higher Quick Ratio than Revance Therapeutics Inc in third quarter 2024. While Quick Ratio total ranking in the third quarter 2024 has deteriorated compared to the prior quarter from 1011 to 1064.

Explain Quick Ratio?
How much Cash & cash equivalents RVNC´s has?
What are RVNC´s Current Liabilities?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

RVNC Quick Ratio (Sep 30 2024)
Q3		 (Jun 30 2024)
Q2		 (Mar 31 2024)
Q1		 (Dec 31 2023)
Q4		 (Sep 30 2023)
Q3
Y / Y Current Liabilities Change -2.57 % 26.39 % -33.33 % 16.62 % 9.94 %
Y / Y Cash & cash equivalent Change -38.59 % -27.34 % 1.24 % -25.31 % -20.63 %
Quick Ratio MRQ 2.31 2.48 5.34 2.88 3.66
RVNC's Total Ranking # 1064 # 1011 # 313 # 385 # 797
Seq. Current Liabilities Change -14.51 % 80.09 % -41.09 % 7.43 % 10.91 %
Seq. Cash & cash equivalent Change -20.63 % -16.25 % 9.1 % -15.33 % -6.09 %



Quick Ratio third quarter 2024 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 274
Healthcare Sector # 487
Overall Market # 1064


Quick Ratio Statistics
High Average Low
28.35 10.37 2.31
(Dec 31 2015)   (Sep 30 2024)




Financial Statements
Revance Therapeutics Inc 's Current Liabilities $ 80 Millions Visit RVNC's Balance sheet
Revance Therapeutics Inc 's Cash & cash equivalent $ 185 Millions Visit RVNC's Balance sheet
Source of RVNC's Sales Visit RVNC's Sales by Geography


Cumulative Revance Therapeutics Inc 's Quick Ratio

RVNC's Quick Ratio for the trailling 12 Months

RVNC Quick Ratio

 (Sep 30 2024)
12 Months		 (Jun 30 2024)
12 Months		 (Mar 31 2024)
12 Months		 (Dec 31 2023)
12 Months		 (Sep 30 2023)
12 Months
Y / Y Current Liabilities TTM Growth 1.3 % 4.49 % -2.99 % 7.96 % 12.2 %
Y / Y Cash & cash equivalent TTM Growth -23.17 % -18.91 % -6.09 % -5.47 % -6.51 %
Quick Ratio TTM 3.02 3.37 3.89 3.56 3.99
Total Ranking TTM # 970 # 828 # 754 # 906 # 823
Seq. Current Liabilities TTM Growth -0.67 % 6.59 % -8.06 % 4.06 % 2.46 %
Seq. Cash & cash equivalent TTM Growth -10.89 % -7.59 % 0.3 % -6.98 % -5.95 %

Quick ratio ranking by company, industry and sector >> Back to RVNC Financial Strength Comparisons >> Go to Compare RVNC Quick Ratio to its Competitors

On the trailing twelve months basis In spite of the year on year decrease in RVNC's Current Liabilities to $80.05 millions, cumulative Quick Ratio to 3.02 below the RVNC average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 465 other companies have achieved higher Quick Ratio than Revance Therapeutics Inc . While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the second quarter 2024 from 3205 to 3343.

Explain Quick Ratio?
How much Cash & cash equivalents RVNC´s has?
What are RVNC´s Current Liabilities?

TTM Quick Ratio Company Ranking
Within: No.
Within the Major Pharmaceutical Preparations Industry # 466
Healthcare Sector # 961
Within the Market # 1064


trailing twelve months Quick Ratio Statistics
High Average Low
14.65 4.78 1.24
(Jun 30 2015)   (Sep 30 2024)




Companies with similar Quick Ratio in the quarter ending Sep 30 2024, within Major Pharmaceutical Preparations Industry Quick RatioSep 30 2024 MRQ Cash & cash equivalentSep 30 2024 MRQ Current Liabilities
Cogent Biosciences Inc   6.32 $ 335.519  Millions$ 53.048  Millions
Xoma Royalty Corporation  6.31 $ 142.050  Millions$ 22.502  Millions
Adial Pharmaceuticals Inc   6.28 $ 5.204  Millions$ 0.829  Millions
Belite Bio Inc  6.27 $ 36.226  Millions$ 5.774  Millions
Eledon Pharmaceuticals Inc   6.26 $ 78.191  Millions$ 12.489  Millions
Q32 Bio Inc   6.19 $ 89.078  Millions$ 14.383  Millions
Generation Bio Co   6.13 $ 184.770  Millions$ 30.165  Millions
Scpharmaceuticals Inc   6.09 $ 91.484  Millions$ 15.033  Millions
Ovid Therapeutics Inc   6.08 $ 62.712  Millions$ 10.317  Millions
Intra cellular Therapies Inc   6.06 $ 1,006.562  Millions$ 166.113  Millions
Opus Genetics Inc   6.02 $ 36.635  Millions$ 6.089  Millions
Mira Pharmaceuticals Inc   5.98 $ 4.145  Millions$ 0.693  Millions
Arrowhead Pharmaceuticals Inc   5.97 $ 578.276  Millions$ 96.826  Millions
Abeona Therapeutics Inc   5.95 $ 109.701  Millions$ 18.422  Millions
Minerva Neurosciences Inc   5.92 $ 26.529  Millions$ 4.483  Millions
Rocket Pharmaceuticals Inc   5.89 $ 235.662  Millions$ 39.980  Millions
Phio Pharmaceuticals Corp  5.87 $ 5.390  Millions$ 0.919  Millions
Ataibeckley Inc   5.85 $ 100.920  Millions$ 17.237  Millions
Allakos Inc   5.80 $ 92.715  Millions$ 15.981  Millions
Repare Therapeutics Inc   5.77 $ 179.432  Millions$ 31.084  Millions
Madrigal Pharmaceuticals Inc   5.64 $ 998.627  Millions$ 176.969  Millions
Vyne Therapeutics Inc   5.60 $ 70.232  Millions$ 12.538  Millions
Tvardi Therapeutics Inc   5.60 $ 37.061  Millions$ 6.622  Millions
Inmed Pharmaceuticals Inc  5.56 $ 5.626  Millions$ 1.012  Millions
Calcimedica Inc   5.45 $ 14.603  Millions$ 2.679  Millions
Bullfrog Ai Holdings Inc   5.44 $ 4.239  Millions$ 0.779  Millions
Renovorx Inc   5.40 $ 9.563  Millions$ 1.772  Millions
Monopar Therapeutics Inc   5.36 $ 6.020  Millions$ 1.123  Millions
Azitra Inc   5.31 $ 7.260  Millions$ 1.368  Millions
Phathom Pharmaceuticals Inc   5.13 $ 334.678  Millions$ 65.288  Millions

Date modified: 2026-08-29T17:18:21+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.